Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
2011

Antiangiogenic Agents for Glioblastoma Treatment

Sample size: 167 publication Evidence: moderate

Author Information

Author(s): Kathryn Beal, Lauren E. Abrey, Philip H. Gutin

Primary Institution: Memorial Sloan-Kettering Cancer Center

Hypothesis

Can antiangiogenic therapies improve outcomes in patients with recurrent or newly diagnosed glioblastoma?

Conclusion

Antiangiogenic therapies, particularly bevacizumab, show promise in improving survival rates for patients with recurrent glioblastoma.

Supporting Evidence

  • Bevacizumab alone achieved a 6-month progression-free survival rate of 42.6%.
  • The combination of bevacizumab and irinotecan resulted in a median overall survival of 8.9 months.
  • Patients treated with bevacizumab had a response rate of 37.8%.

Takeaway

Doctors are testing special medicines that can help stop brain tumors from growing by blocking blood vessels. One of these medicines, called bevacizumab, has helped some patients live longer.

Methodology

The study analyzed data from phase II trials evaluating the efficacy of bevacizumab alone and in combination with irinotecan in patients with recurrent glioblastoma.

Potential Biases

Potential biases may arise from the non-comparative nature of the trials and the reliance on historical controls.

Limitations

The study primarily focuses on phase II trials, which may not provide definitive evidence of efficacy compared to larger phase III trials.

Participant Demographics

Patients included in the trials were primarily adults with recurrent glioblastoma.

Statistical Information

P-Value

p < 0.0001

Confidence Interval

95% CI, 29.6%-55.5%

Statistical Significance

p < 0.0001

Digital Object Identifier (DOI)

10.1186/1748-717X-6-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication